Endpoints News

The biopharma world is here. Get the industry’s most comprehensive daily news reports at

[Endpoints News @endpts]

China hawks are gaining the upper hand in Washington.
https://t.co/vF026SKddj

[Endpoints News @endpts]

Innovent posts a Phase 3 win for the gastric cancer ADC that drew Takeda's attention.
https://t.co/9CqXtjrvor

[Endpoints News @endpts]

In this week's Peer Review: Uli Stilz heads to Flagship; Revolution Medicines adds a commercial lead.
https://t.co/cUw2CCS5Tf

[Endpoints News @endpts]

Eli Lilly is halving a €2.3B investment in Germany after Berlin proposed sweeping healthcare cuts, warning the country risks becoming its least attractive European market. https://t.co/x2YFLrObDo

[Endpoints News @endpts]

⚡️Exclusive: Acting FDA head not interested in permanent job https://t.co/DqTbm6wkxV

[Endpoints News @endpts]

The Supreme Court unanimously sided with Hikma in a closely watched skinny label case, ruling that Amarin failed to show Hikma actively encouraged infringement of its Vascepa patents. https://t.co/QfLA668MVo

[Endpoints News @endpts]

Ona Therapeutics raised $86.6M to push two ADC candidates into the clinic. https://t.co/kHqh2z4Q3V

[Endpoints News @endpts]

Zynlonta's confirmatory trial showed a fatal event rate nearly 3x the control arm, sending shares down 50%. https://t.co/3YMQBP6Vyh

[Endpoints News @endpts]

Alnylam signs its first AI discovery deal with Inceptive, paying $30M upfront in a partnership that could reach $2B. https://t.co/z2ozMEJgci

[Endpoints News @endpts]

Mineralys lines up financing as its hypertension drug nears approval.
https://t.co/U93iU7SSfm

[Endpoints News @endpts]

Regeneron is standing by CytomX, even as other pharma alliances have ended.
https://t.co/vmsYuZMRB4

[Endpoints News @endpts]

Lilly enters RNA editing with a $1.9B Ascidian deal targeting kidney disease.
https://t.co/Ztlpq8RNQe

[Endpoints News @endpts]

VEGF-targeting bispecifics dominated the oncology conversation at ASCO, but whether they can beat Keytruda — or just fill in where it falls short — remains an open question. https://t.co/Tze3oi4H2w

[Endpoints News @endpts]

Travere is paying Everest Medicines $112M upfront to license a BTK inhibitor targeting rare kidney diseases, expanding its pipeline beyond its approved drug Filspari. https://t.co/lMCmr90NeU

[Endpoints News @endpts]

Legend Biotech reported early in vivo CAR-T data showing a 50% response rate in lymphoma patients, with all higher-dose patients responding. https://t.co/adiwNrVTQq

[Endpoints News @endpts]

Fulcrum is shelving its only clinical asset and seeking a strategic exit after the FDA flagged cancer risk concerns, sending shares down by half. https://t.co/RXNx79KF0F

[Endpoints News @endpts]

Abivax's Phase 3 maintenance data in ulcerative colitis drew scrutiny over malignancy events in the high-dose group, sending shares down as much as 31%. https://t.co/bXZQmt2sxy

[Endpoints News @endpts]

Exclusive: A bipartisan bill from Michigan lawmakers would require national security screening of US biotech investments in China, targeting the surge in cross-border deals. https://t.co/XpZ5kPQa0a

[Endpoints News @endpts]

Servier bets $1.55B on Edgewise's muscular dystrophy drugs.
https://t.co/ZAf10u8VyT

[Endpoints News @endpts]

Oculis hits a Phase 3 wall with its diabetic macular edema eye drops.
https://t.co/QDeOQDcXU5